Side-by-side comparison of AI visibility scores, market position, and capabilities
Doctronic became the first AI to legally renew prescriptions in the US (190-med formulary, Utah); raised $40M Series B with 300K+ visitors as it expands state by state (March 2026).
Doctronic is a US-based AI telehealth company that has built a regulatory-compliant AI platform for medical consultations and prescription services. The company made history by becoming the first AI to legally renew prescriptions in the United States, initially operating in Utah under a pioneering regulatory framework that allows AI-assisted prescribing for a defined formulary of medications. Doctronic's platform enables patients to consult with an AI for common, well-understood health conditions and receive prescriptions for up to 190 medications without requiring a synchronous visit with a human physician.\n\nDoctronic's platform is designed to navigate the complex intersection of AI capability, medical regulation, and patient safety. Its AI conducts structured medical history intake, symptom assessment, and contraindication screening before generating prescription recommendations that are reviewed within a compliance framework. The platform targets patients seeking convenient, affordable access to prescription renewals and routine care for chronic and common conditions—a massive market given the primary care shortage in the United States. Doctronic operates at the forefront of AI in regulated healthcare, demonstrating that AI can deliver clinically appropriate care within legal guardrails.\n\nDoctronic raised a $40M Series B in 2026 to accelerate geographic expansion and broaden its formulary and condition coverage. With over 300,000 visitors to its platform, Doctronic has demonstrated real consumer demand for AI-mediated healthcare access. The company's Utah-first strategy allowed it to build a compliant, proven model before pursuing expansion to additional states with favorable telehealth regulations. As regulatory frameworks for AI in medicine evolve, Doctronic is positioned as a first-mover with a defensible regulatory and clinical knowledge base.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.